Denosumab's Effect on Muscle Strength and Insulin Sensitivity in People With Osteoporosis
Tests denosumab against saline for muscle strength and insulin response in osteoporosis.
Plain-language title generated from the registry record
Registry title: The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity
Key facts
- Where
- Aarhus N, DenmarkSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for postmenopausal women with type 2 diabetes who take metformin alone, to study how denosumab affects muscle strength and insulin sensitivity.
- Age
- 40 to 64 years
- Sex
- Women only
- Disease stage
- Postmenopausal for at least two years; type 2 diabetes; BMD T-score ≥ -2.0; at least 2 lumbar vertebrae that can be checked by DXA scan.
- Earlier treatment
- Must be treated with metformin alone. Must never have had treatment for osteoporosis.
Main reasons for not taking part
- Any other diabetes medicine than metformin
- Low-energy vertebral or hip fracture at any time
- Ongoing treatment with systemic glucocorticoids
- Active cancer within the last 5 years (basal cell skin cancer is allowed)
- eGFR ≤ 35 mL/min
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 64 years old?
Source: NCT07271771, who can take part
Where in Denmark
- Region MidtjyllandAarhus N, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Aarhus University Hospital
- Trial code
- NCT07271771EU 2024-510637-18-00
- Record updated
- 15 December 2025
- Original description
Randomized, placebo controlled prospective trial evaluating the effect of denosumab on insulin sensitivity and muscle strength.Read full original descriptionShow less
The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity
Randomized, placebo controlled prospective trial evaluating the effect of denosumab on insulin sensitivity and muscle strength.
Inclusion: Postmenopausal women (postmenopausal for at least two years); Age ≥ 40 years; BMD T-score ≥ -2.0 (lumbar spine, total hip or femoral neck); At least 2 lumbar vertebrae that can be evaluated by dual-energy x-ray absorptiometry (DXA); Diabetes Mellitus type 2; Treatment with metformin as monotherapy.
Exclusion: Other antidiabetic medication than metformin; Ongoing treatment with systemic glucocorticoids; Metabolic bone disease (for example osteogenesis imperfecta, Paget's disease of bone, hyperparathyroidism); Active cancer within the last 5 years with the exception of basal cell skin cancer; Treatment affecting bone, calcium metabolism or muscle; Estimated glomerular filtration rate (eGFR) ≤ 35 mL/min; Treatment for osteoporosis at any time; Low-energy vertebral fractures at any time; Low-energy hip fracture at any time; Unable to read and understand Danish; Immobility.